corpora lutea. Injection of mice with control FDC-P1 cells led to comparable organ engraftment, but the mice developed none of these lesions. The observations suggest that LIF may be a potent cachexia-inducing agent and may have marked effects on osteoblasts and calcium metabolism.
The leukemia inhibitory factor (LIF) was purified (1, 2) and a LIF cDNA was cloned (3) on the basis of its capacity to induce differentiation in and to suppress cells of the murine myeloid leukemic line Ml. LIF has been reported to have proliferative effects on one hemopoietic cell line (4) but not on normal hemopoietic progenitor cells (5) , although LIF receptors are present on cells of the monocyte-macrophage lineage (6) . Evidence of broader actions of LIF has come from the observations that LIF can release calcium from bone tissue in vitro (7) and has a powerful in vitro action in suppressing differentiation in normal pluripotential embryonic stem cells (8) .
In the present experiments, mice were engrafted with a hemopoietic cell line modified to produce high levels of LIF in an attempt to induce tissue changes that might provide further clues to the physiological functions of this molecule.
MATERIALS AND METHODS
Mice. Mice used were female 8-to 12-week-old DBA/2J mice and were raised in this Institute under specific pathogen-free conditions. Construction and Selection of LIF Retrovirus. The 629-base-pair (bp) EcoRI-Xba I fragment of LIF cDNA from pLIFNK3 (9) was ligated into the EcoRI-Xba I site of pIC-20H (10) . The LIF cDNA fragment was then excised as a Sal I-Xho I fragment and ligated into the Xho I site of pMPZen (11) . Helper-free MPZen(LIF) virus-producing fibroblast lines were made by cotransfecting T 2 cells (12) with pSV2-neo (13) and pMPZen(LIF) as described (11) . The lines were screened initially for LIF production and then for their efficiency in infecting FDC-P1 cells (FD cells) (11 
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At autopsy, tissues were fixed in 10% Formol/saline and then blocked in paraffin, sectioned, and stained with hematoxylin and eosin or other stains.
LIF Assays. Serial 1:1 dilutions of 0.1 ml of material to be assayed for LIF content were added to 1 ml of agar medium cultures containing 300 Ml leukemic cells. After 7 days of incubation, the percentage of differentiated colonies was determined in each culture (5) . LIF units were determined on the basis that 50 units/ml is the concentration inducing half of the Ml colonies to differentiate. Assays were standardized by the use of purified recombinant LIF preparations of known activity.
RESULTS
General Results. Commencing 10 days after the injection of FD/LIF cells, some irradiated recipient mice began to show weight loss, ruffled hair, and an irritable behavior. Within days of exhibiting these signs, such mice became moribund, and 90% of irradiated recipients developed this syndrome within 40 days of injection (Fig. 1 Medical Sciences: Metcalf and Gearing spleen enlargement, small adrenals of red color, and, in three mice, plaques of calcification on the surface of the liver.
No histological abnormalities were seen in control mice injected with FD cells other than occasional small foci of FD cells in the spleen or mesenteric node and, in three mice, small areas of calcification in the heart. In contrast, multiple histological abnormalities were observed in FD/LIF mice (Table 1, Fig. 3) .
Remarkable changes were evident in the ends of the long bones and in the sternum of all recipients of FD/LIF cells. sionally prominent osteoclasts, there was clear overall excess new bone formation, most evident as the formation of irregularly shaped trabeculae of bone occupying the marrow cavity ( Fig. 3 B and C) , an appearance resembling myelosclerosis. The excess new bone formation prevented attempts to insert a needle and flush marrow cells from the femur in-10 of 19 irradiated recipients and 11 of 19 unirradiated recipients of FD/LIF cells. Focal areas of calcification were present in the myocardium of two-thirds of irradiated and unirradiated recipients of FD/LIF cells (Fig. 3D) . Similar foci were present in skeletal muscle of many recipients but were less frequent in irradiated recipients (Table 1) . Calcification appeared to initiate within the muscle cells and, unless the area was large, there was no associated cellular infiltration.
Liver parenchymal cells in recipients of FD/LIF cells were reduced in volume with dilation of the vessels. Most livers showed focal areas of extramedullary hemopoiesis and, particularly in unirradiated recipients, necrotic areas. Fibrosis around portal vessels was relatively common in irradiated recipients. A low percentage of the livers showed extensive foci of calcification, and such livers always showed necrotic areas.
The spleen was moderately enlarged with lymphoid follicle atrophy and excess hemopoiesis in the red pulp. The thymus was atrophic in all recipients of FD/LIF cells, with complete loss of cortical lymphocytes. The thymus cortex was normal in irradiated mice injected with FD cells. The pancreas showed dispersion of individual acini due to edema, with reduction in size and/or patchy necrosis of acinar cells and, in half of the unirradiated recipients, some infiltration mainly by mononuclear cells and granulocytes (Fig. 3F) . The pancreatic islets were intact, and the mice showed no glucosuria.
The adrenals in mice injected with FD cells showed a prominent zone of lipid-containing cells in the inner cortex ("brown degeneration"), typical of DBA/2 mice. This zone was absent in most mice injected with FD/LIF cells, with reduction in organ size.
The ovaries of unirradiated, but not irradiated, recipients of FD/LIF cells were surrounded by an abnormal cellular capsule mainly containing lymphocytes. The frequency and maturation of ovarian follicles in FD/LIF recipients were not significantly altered, but there was a striking deficit of corpora lutea (Fig. 3H) . Those that were present tended to be ill-defined with luteal cells of small volume.
Other than a reduction in cellular volume, no abnormalities were detected in recipients of FD/LIF cells in the lung, salivary gland, kidney, bladder, gut, mesenteric lymph node, brain, thyroid, or parathyroids.
DISCUSSION
After injection of FD cells into syngeneic DBA/2 mice, a progressively increasing population ofthese cells accumulates in the marrow, spleen, and lymphoid tissues (U. Duhrsen and D.M., unpublished data). FD/LIF cells exhibited the same behavior and, as in previous studies using FD cells, the cellular accumulation was accelerated by preirradiating the recipients (17) . Analyses for LIF mRNA and bioassays for LIF indicated that active production of LIF occurred in the marrow, spleen, and mesenteric node of recipients of FD/LIF cells, and there was a substantial elevation of circulating LIF levels. No elevation of LIF production or serum LIF levels was seen in control mice injected with FD cells.
In mice containing FD/LIF cells, a fatal cachexia developed within an interval as short as 12 days. The mice exhibited a novel syndrome of bone overgrowth with associated extramedullary hemopoiesis in the spleen and liver, calcification in muscle tissue and liver, pancreatitis, thymus atrophy, and adrenal and ovarian changes.
None of these abnormalities developed in irradiated or unirradiated recipients of FD cells, suggesting that the abnormalities were the consequence of excess LIF levels. The changes in the bone and bone marrow may have been associated with local production of LIF by resident FD/LIF cells. However, other organs such as the pancreas, muscle, and ovaries contained no obvious FD/LIF cells and, if the lesions were directly initiated by LIF, the LIF must have reached these tissues via the circulation.
The observed tissue damage might either have been the consequence of direct actions of LIF on these various cells or have been mediated indirectly by some LIF-initiated product. Osteoblasts exhibit LIF receptors, and the pancreas can bind significant amounts of injected '25I-labeled LIF (D. J. Hilton, N. A. Nicola, and D.M., unpublished data). Potentially, therefore, the accumulation of osteoblasts with excess new bone formation and the pancreatic damage may have been direct effects of excess LIF stimulation.
The only agent previously known to induce cachexia is tumor necrosis factor (18) . LIF may be another such agent or may merely induce the production of tumor necrosis factor. Many of the changes such as reduction in organ parenchymal volume, thymus cortex atrophy, loss of adrenal lipid, and defective corpora lutea formation may merely be secondary consequences of the cachectic state. The early death of some irradiated recipients of FD/LIF cells might be the combined consequence of irradiation-induced hemopoietic aplasia and organ damage plus early toxic effects of LIF.
The most consistent tissue abnormalities were an increased number of osteoblasts in the bone marrow with excess new bone formation, often in animals with increased bone resorption and calcium deposition in muscle tissue. Previous in vitro studies showed an ability of LIF to induce calcium release from bone tissue in vitro (7) . The combination of new bone formation, bone resorption, and calcium deposition in tissues suggests a novel perturbation of calcium metabolism.
The experiments suggest that LIF, in excess concentrations, may be a highly toxic agent but that LIF may play a normal role in regulating bone formation and calcium metabolism. The latter findings suggest that LIF may have a clinical application in promoting new bone formation and calcification.
In the present animals engrafted with LIF-producing cells, the abnormalities induced offer unusual models for investigating disease states such as osteosclerosis, pancreatitis, and cachexia. The engraftment model has the potential to be extended to study the long-term effects of excess levels of any factor able to be produced by FD cells after retroviral insertion of the appropriate cDNA.
